The scarlet letter of alkylation: A mini review of selective alkylating agents

Translational Oncology

Volumn 5, Issue 4, 2012, Pages 226-229

  Oronsky, Bryan T ^a   Reid, Tony ^b   Knox, Susan J ^c   Scicinski, Jan J ^a  

^a Toyota InfoTechnology Center USA Inc   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; NUCLEOPHILE; PRODRUG; PYRUVIC ACID DERIVATIVE; RRX 001; TH 302; UNCLASSIFIED DRUG;

ALKYLATION; ANTINEOPLASTIC ACTIVITY; CHEMICAL BOND; DRUG BINDING; DRUG MECHANISM; DRUG PENETRATION; DRUG STRUCTURE; OXIDATION REDUCTION REACTION; REVIEW; STIGMA;

EID: 84865460976     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12187     Document Type: Article

References (13)

1. Guterman L (2011). Covalent drugs form long-lived ties-irreversible inhibitors may provide unique benefits in drug development. Chem Eng News 89, 19-26.
2. Potashman MH and Duggan ME (2009). Covalent modifiers: an orthogonal approach to drug design. J Med Chem 52, 1231-1246.
3. Singh J, Petter RC, Baillie TA, and Whitty A (2011). The resurgence of covalent drugs. Nat Rev Drug Discov 10, 307-317.
4. Siddik ZH (2002). Mechanisms of action of cancer chemotherapeutic agents: DNA-interactive alkylating agents and antitumour platinum-based drugs. In The Cancer Handbook. Nature Publishing Group, London, UK. pp. 1295-1313.
5. Lepore SD and Mondal D (2007). Recent advances in heterolytic nucleofugal leaving groups. Tetrahedron 63, 5103-5122.
6. Warwick GP (1963). The mechanism of action of alkylating agents. Cancer Res 23, 1315-1333.
7. 14C-RRx-001 in rats after a single intravenous administration and in blood from rats, dogs, monkeys, and humans. In 17th North American Regional ISSX Meeting, Atlanta, GA p. P81.
8. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, and Pedersen PL (2004). Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 324, 269-275.
9. Mathupala SP, Ko YH, and Pedersen PL (2009). Hexokinase-2 bound to mitochondria: cancer's stygian link to the Warburg effect and a pivotal target for effective therapy. Semin Cancer Biol 19, 17-24.
10. Geschwind JF, Ko YH, Torbenson MS, Magee C, and Pedersen PL (2002). Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 62, 3909-3913.
11. Vali M, Liapi E, Kowalski J, Hong K, Khwaja A, Torbenson MS, Georgiades C, and Geschwind JF (2007). Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer. J Vasc Intery Radiol 18, 95-101.
12. Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, et al. (2011). Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res 18, 758-770.
13. Oronsky BT, Knox SJ, and Scicinski J (2011). Six degrees of separation: the oxygen effect in the development of radiosensitizers. Transl Oncol 4, 189-198.